Kallikrein 6 and kallikrein 10 overexpression has been shown to correlate with intrinsic resistance to adjuvant chemotherapy and with a poor prognosis in ovarian cancer patients (Diamandis et al, 2003; Luo et al, 2003). Here, KLK6 is linked to ovarian carcinoma.